Financing ·
Quince Therapeutics, Inc. announced plans to hold a special meeting of stockholders to approve the issuance of common…
QNCXIRulya Therapeutics Inc.
Quince Therapeutics, Inc. announced plans to hold a special meeting of stockholders to approve the issuance of common stock upon conversion of its Series C Non-Voting Convertible Preferred Stock and exercise of related warrants. This issuance is required because it will represent more than 20% of outstanding shares and may trigger a change of control under Nasdaq Listing Rules. The company also filed unaudited pro forma financial information as of June 30, 2026, reflecting the conversion of approximately 211,302 preferred shares into roughly 10.99 million common shares. This follows the May 2026 acquisition of Orphai Therapeutics and a concurrent $115 million PIPE financing involving Series C Preferred Stock issued at $797.50 per share. Quince Therapeutics operates in the biotechnology industry, focusing on developing treatments for rare diseases.